ArticleTherapeutic advances in medical oncology2022

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).

Shigeru Tanzawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.